A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Escalation Study for the Evaluation of the Safety, Tolerability, and Pharmacokinetics of Recombinant Human Plasma Gelsolin (rhu-pGSN) Following Intravenous Administration to Healthy Volunteers

This Phase 1, randomized, double-blind, placebo-controlled study demonstrated that intravenous recombinant human plasma gelsolin (rhu-pGSN) is safe, well-tolerated, and exhibits a half-life supporting once-daily dosing in healthy volunteers at doses up to 24 mg/kg.

The Gist

The Big Picture: A "Fire Extinguisher" Test

Imagine your body is a house. Sometimes, due to infections or injuries, the house catches fire. This fire isn't just burning; it's causing the walls to crumble and the smoke to get so thick that the air becomes unbreathable. This is what happens in severe lung conditions like ARDS (Acute Respiratory Distress Syndrome).

Your body naturally has a "fire extinguisher" called Plasma Gelsolin (pGSN). It's a protein that floats in your blood, cleaning up the smoke (inflammation) and putting out the fire. But when people get very sick, their supply of this protein runs out, and the fire gets worse.

Scientists at BioAegis Therapeutics created a man-made version of this protein, called rhu-pGSN, to act as a backup fire extinguisher. Before they could test it on sick people, they had to make sure it was safe to pour into healthy people. That is exactly what this study did.

The Experiment: The "Safety Check"

Think of this study as a test drive for a new car engine before putting it in a race car.

• The Drivers: They recruited 32 healthy volunteers (people with no serious illnesses).
• The Car: The "engine" was the new drug, rhu-pGSN.
• The Test: They split the volunteers into four groups. Each group got a different amount of the drug, starting with a small sip and going up to a large gulp (doses ranging from 6 mg to 24 mg per kilogram of body weight).
• The Schedule: Instead of just one dose, they gave them five doses over four days. This was to see if the drug built up in the body or caused problems after repeated use.
• The Control: Some people got the real drug, and some got a "sugar pill" (saline placebo) so the scientists could tell if any side effects were actually caused by the drug or just by being in a study.

What They Found: The "Safety Report"

After the test drive, the scientists checked the dashboard for any warning lights.

1. No Crashes (Safety): The drug was safe and well-tolerated.

   • Most people felt fine.
   • A few people had minor side effects, like a mild headache, a bit of nausea, or some skin irritation. Think of these as minor "squeaks" in the car, not engine failures.
   • Crucially: No one had a serious reaction, no one had to stop the study, and no one died. The "fire extinguisher" didn't accidentally spray the wrong chemicals.

2. How Long It Lasted (Pharmacokinetics):

   • The scientists wanted to know: "If we give this drug, how long does it stay in the blood?"
   • They found that the drug stays in the system for a long time—about 14 to 28 hours on average.
   • The Analogy: Imagine pouring water into a bucket with a small hole. The water (the drug) stays in the bucket long enough that you don't need to pour more every hour. You only need to top it off once a day. This is great news because it means future treatments could be simple: one IV drip a day.

3. Did the Body Fight Back? (Immunogenicity):

   • Sometimes, the body sees a new protein and thinks, "Hey, that's an invader!" and creates antibodies to attack it.
   • The scientists checked to see if the volunteers' bodies started fighting the drug. The answer was no. The body accepted the new protein without throwing a tantrum.

The "Oops" Moment (A Technical Note)

There was a small twist in the story. After the study was done, the scientists realized they had been measuring the "strength" of the drug slightly wrong. It turned out the doses they thought they were giving were actually 11% stronger than they calculated.

• Why this matters: Even though they accidentally gave a slightly higher dose than planned, the drug was still safe. This actually makes the results even more reassuring!

The Bottom Line: What's Next?

This study was the "Phase 1" test. It proved that the new "fire extinguisher" (rhu-pGSN) is safe to use in humans and stays in the body long enough to be practical.

The Next Step: Now that they know it's safe, they are moving to Phase 2. This is where they will test the drug on people who are actually sick with severe lung infections (like pneumonia or ARDS) to see if it actually helps them breathe better and recover faster.

In short: The scientists built a new tool to help put out the body's internal fires. They tested it on healthy people, and it worked perfectly without causing any damage. Now, they are ready to try it on the people who really need it.

Technical Summary

1. Problem Statement & Background

• Clinical Context: Acute Respiratory Distress Syndrome (ARDS) and Acute Lung Injury (ALI) are characterized by dysregulated inflammation. Endogenous plasma gelsolin (pGSN), a non-immunosuppressive anti-inflammatory protein, is known to be depleted in severe acute illnesses (e.g., sepsis, pneumonia, COVID-19), with lower levels correlating to worse prognoses.
• Therapeutic Gap: While preclinical animal models have demonstrated that administering recombinant human pGSN (rhu-pGSN) improves outcomes in lung injury models, clinical data in humans has been limited to small trials in mild community-acquired pneumonia (CAP) and moderate-to-severe COVID-19.
• Objective: There was a need to establish a comprehensive safety, tolerability, and pharmacokinetic (PK) profile for rhu-pGSN in healthy volunteers using a multiple-dose escalation regimen to support the design of a Phase 2 trial for moderate-to-severe ARDS.

2. Methodology

• Study Design: A Phase 1, single-center, randomized, double-blind, placebo-controlled, multiple-dose escalation study.
• Setting & Population: Conducted at Nucleus Network (Saint Paul, MN) between February and May 2023.
  • Participants: 32 healthy volunteers (aged 18–55, BMI < 30 kg/m²).
  • Randomization: Participants were assigned to 4 sequentially ascending dose cohorts (6, 12, 18, and 24 mg/kg). Each cohort included 8 subjects randomized 3:1 (6 rhu-pGSN : 2 placebo).
• Intervention:
  • Drug: rhu-pGSN produced in E. coli, lyophilized, and reconstituted to 40 mg/mL.
  • Dosing Schedule: Five intravenous (IV) infusions administered at 0, 12, 36, 60, and 84 hours.
  • Control: Saline placebo.
• Outcomes Measured:
  • Primary: Incidence and severity of Adverse Events (AEs) and laboratory abnormalities.
  • Secondary: Pharmacokinetics (PK) including $C_{max}$, $T_{max}$, half-life ($t_{1/2}$), and Area Under the Curve (AUC); immunogenicity (anti-rhu-pGSN antibodies) at Day 28.
• Analytical Methods:
  • PK: Measured via ELISA with baseline adjustment (subtracting endogenous pGSN levels).
  • Immunogenicity: Three-tier Meso Scale Diagnostics (MSD) electrochemiluminescent immunoassay (Screening, Confirmatory, Titration).
  • Note on Dosage: A footnote clarifies that due to a historical error in the extinction coefficient, the actual protein concentration administered was 11% higher than the reported mg/kg values.

3. Key Contributions

• Safety Expansion: This study significantly expands the safety profile of rhu-pGSN beyond previous trials limited to 1–3 doses, evaluating a rigorous 5-dose regimen up to 24 mg/kg.
• Pharmacokinetic Characterization: It provides the first detailed PK data for multiple-dose rhu-pGSN in humans, establishing that the drug achieves sustained supraphysiological levels without significant accumulation.
• Immunogenicity Data: It offers critical data on the development of anti-drug antibodies (ADA) following repeated dosing, a crucial factor for chronic or repeated therapeutic use.
• Dosing Strategy Validation: The results support a once-daily IV dosing schedule for future trials based on the drug's half-life.

4. Results

• Safety & Tolerability:
  • Adverse Events (AEs): 10 of 24 (41.7%) rhu-pGSN subjects reported 13 AEs; 1 of 8 (12.5%) placebo subjects reported 1 AE.
  • Severity: All AEs were mild or moderate. No Serious Adverse Events (SAEs) occurred, and no subjects discontinued due to AEs.
  • Related AEs: Only 3 subjects (12.5%) had AEs assessed as related to the study drug (constipation, fatigue, epigastric discomfort).
  • Systemic Impact: No significant differences were observed between treatment and placebo groups regarding vital signs, EKG findings, or clinical laboratory abnormalities.
• Pharmacokinetics:
  • Exposure: A dose-dependent increase in plasma concentrations was observed. At higher doses (18 and 24 mg/kg), peak concentrations exceeded 10-fold the physiological baseline.
  • Half-Life: The median half-life ($t_{1/2}$) across all regimens was 14.5 hours (range 9.2–28.4 hours), supporting once-daily dosing.
  • Accumulation: Repeated dosing did not lead to significant drug accumulation; levels returned to near-baseline by Day 28.
• Immunogenicity:
  • No confirmed anti-rhu-pGSN antibodies were detected in the rhu-pGSN group at Day 28.
  • One placebo subject and one 24 mg/kg subject showed signals in screening/confirmation tiers, but subsequent titration assays showed near-baseline signals, leading to a conclusion of negative immunogenicity for the study population.

5. Significance

• Clinical Translation: The study confirms that high-dose, multiple-dose IV rhu-pGSN is safe and well-tolerated in humans, validating the transition from preclinical models to human therapeutic application.
• Trial Design Support: The PK data (median half-life >14h) directly informs the dosing schedule for the ongoing Phase 2 proof-of-concept trial (NCT05947955) in patients with moderate-to-severe ARDS.
• Therapeutic Potential: By demonstrating that rhu-pGSN can safely elevate plasma levels to supraphysiological ranges without triggering immune responses or severe toxicity, the study strengthens the hypothesis that pGSN replacement is a viable strategy for modulating inflammation in critical lung injury.

Conclusion: The study successfully establishes the safety and pharmacokinetic foundation for rhu-pGSN as a potential therapeutic for ARDS, supporting the initiation of efficacy trials in critically ill patients.